April 30, 2021
A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
TYPE OF SARCOMA: Refractory Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcomas, Rhabdomyosarcoma, Mesenchymal Chondrosarcoma
DRUG: Regorafenib
ACCRUAL STATUS: Recruiting
OVERALL STUDY PRINCIPAL INVESTIGATOR:
Robert Maki, MD, PhD
Professor of Medicine
Abramson Cancer Center
University of Pennsylvania School of Medicine
CLINICALTRIALS.GOV IDENTIFIER: NCT02048371
FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV
To learn more about this study or to contact the study research staff: